Longitudinal analyses were conducted in populations without biological confirmation of AD by biomarkers, such as lack of cerebrospinal fluid information (i.e., levels of Aβ and Tau), which may affect the results of pharmacoepidemiologic analyses. Here, MAPT is linked to Alzheimer disease.